Cargando…

Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer

PURPOSE: In 2007, the American Society of Clinical Oncology and the College of American Pathologists had established a human epidermal growth factor receptor 2 (HER2) testing guideline, which was updated in 2013 and subsequently in 2018. We assessed the clinical impact of the recent update by compar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Min Chong, Kang, Su Hwan, Choi, Jung Eun, Bae, Young Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604374/ https://www.ncbi.nlm.nih.gov/pubmed/33154824 http://dx.doi.org/10.4048/jbc.2020.23.e53

Ejemplares similares

Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2023)

Changes in the detection of human epidermal growth factor receptor 2 gene (Her-2) status for Her-2 fluorescent in situ hybridization testing
por: Xu, Ying, et al.
Publicado: (2022)

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
por: Sarkis, Julien, et al.
Publicado: (2020)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
por: Iqbal, Nida, et al.
Publicado: (2014)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression
por: Quddus, M. Ruhul, et al.
Publicado: (2020)

Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
por: Siddiqui, Mohammad R., et al.
Publicado: (2019)

Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing
por: Shin, Saeam, et al.
Publicado: (2022)

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
por: Shin, Daniel Sanghoon, et al.
Publicado: (2016)

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies
por: Schrohl, Anne-Sofie, et al.
Publicado: (2011)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Update on HER-2 as a target for cancer therapy: Alternative strategies for targeting the epidermal growth factor system in cancer
por: Gullick, William J
Publicado: (2001)

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
por: Elshazly, Ahmed M., et al.
Publicado: (2022)

Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach
por: Mudgal, Shikha, et al.
Publicado: (2023)

Association Study of Polymorphisms of Epidermal Growth Factor and Epidermal Growth Factor Receptor With Benign Prostatic Hyperplasia in a Korean Population
por: Kim, Su Kang, et al.
Publicado: (2016)

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients
por: Asgeirsson, Kristjan S, et al.
Publicado: (2007)

The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2019)

Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer
por: Chan, David S. Y., et al.
Publicado: (2012)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
por: McGranahan, Tresa M., et al.
Publicado: (2022)

Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress
por: Budi, Hendrik Setia, et al.
Publicado: (2022)

Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers
por: Lee, So Jeong, et al.
Publicado: (2017)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
por: Kim, Aeri, et al.
Publicado: (2017)

Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status
por: Kim, Aeri, et al.
Publicado: (2012)

Characteristics and Prognosis of Estrogen Receptor Low-Positive Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2022)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients’ Clinical Features
por: Li, Wei, et al.
Publicado: (2018)

Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
por: Li, Cunfu, et al.
Publicado: (2017)

Comparative Analysis of Evolutionarily Conserved Motifs of Epidermal Growth Factor Receptor 2 (HER2) Predicts Novel Potential Therapeutic Epitopes
por: Deng, Xiaohong, et al.
Publicado: (2014)

Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Colorectal Carcinoma: A Potential Area of Focus for Future Diagnostics
por: Kaur, Simrandeep, et al.
Publicado: (2022)

Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alves, Fátima R, et al.
Publicado: (2022)

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
por: Gligorov, Joseph, et al.
Publicado: (2022)

Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer
por: Hong, Chang‐Soo, et al.
Publicado: (2020)

Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer
por: Cho, Dong Hui, et al.
Publicado: (2013)

Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment
por: Akinnusi, Precious A, et al.
Publicado: (2022)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
por: Wu, Qian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7i63dpmm5g1nie9sifekrf36jh